AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in this application:

Listing of claims:

1. (Previously Presented) A disorazole compound of the general formula I



Formula I

in which independently of one another

R1 is:

(i) hydrogen,

(ii) OR4,

(iii) part of a double bond to C5',

R2 and R4 are:

(i) hydrogen,

(ii) unsubstituted or substituted (C_1-C_6)-alkyl,

(iii) (C_1-C_4)-alkyl substituted by one or more fluorine atoms, preferably a trifluoromethyl group,

(iv) unsubstituted or substituted (C_1-C_4)-alkyl-(C_6-C_{14})-aryl, unsubstituted or substituted (C_1-C_4)-alkyl-heteroaryl

(v) (C_1-C_4)-alkoxycarbonyl, (C_1-C_4)-alkylaminocarbonyl (C_1-C_4)-alkylaminothiocarbonyl, (C_1-C_6)-alkyl-carbonyl or (C_1-C_6)-alkoxycarbonyl-(C_1-C_6)-alkyl,

it being possible for the substitution of the alkyl radical by F, Cl, Br, I, CN, NH_2, NH-(C_1-C_{20})-alkyl, NH-(C_3-C_{12})-cycloalkyl, OH, O-(C_1-C_{20})-alkyl to take place singly or, on identical or different atoms, multiply by identical or different substituents, and it being possible for the substitution of an aryl radical by F, Cl, Br, I, CN, NH_2, NH-(C_1-C_{20})-alkyl, OH, O-(C_1-C_{20})-alkyl and/or (C_3-C_8)-heterocyclyl having 1 to 5 heteroatoms, preferably nitrogen, oxygen, sulfur to take place singly or, on identical or different atoms, multiply by identical or different substituents,

R3 is:

(i) unsubstituted or substituted (C_1-C_6)-alkyl,

(ii) (C_1-C_4)-alkyl substituted by one or more fluorine atoms, preferably a trifluoromethyl group,

(iii) unsubstituted or substituted (C_1-C_4)-alkyl-(C_6-C_{14})-aryl, unsubstituted or substituted (C_1-C_4)-alkyl-heteroaryl

(iv) (C_1-C_4)-alkoxycarbonyl, (C_1-C_4)-alkylaminocarbonyl (C_1-C_4)-alkylaminothiocarbonyl, (C_1-C_6)-alkyl-carbonyl or (C_1-C_6)-alkoxycarbonyl-(C_1-C_6)-alkyl,

it being possible for the substitution of the alkyl radical by F, Cl, Br, I, CN, NH_2, NH-(C_1-C_{20})-alkyl, NH-(C_3-C_{12})-cycloalkyl, OH, O-(C_1-C_{20})-alkyl to take place singly or, on identical or different atoms, multiply by identical or different substituents, and it being possible for the substitution of an aryl radical by F, Cl, Br, I, CN, NH_2, NH-(C_1-C_{20})-alkyl, OH, O-(C_1-C_{20})-alkyl and/or (C_3-C_8)-heterocyclyl having 1 to 5 heteroatoms, preferably nitrogen, oxygen, sulfur to take place singly or, on identical or different atoms, multiply by identical or different substituents,

and

X, Y are: in each case individually independently of one another or together oxygen, sulfur, two vicinal hydroxyl groups, two vicinal methoxy groups, part of a double bond,

its tautomers, E/Z isomers, stereoisomers, including the diastereomers and enantiomers, and the physiologically tolerable salts thereof.

2. (Previously Presented) The compound of claim 1, wherein R1 is hydrogen or part of a double bond to C5', and R2 is hydrogen, R3 is methyl and X and Y are, independently of one another, oxygen, sulfur, two vicinal hydroxyl groups, two vicinal methoxy groups, or part of a double bond.

3. (Previously Presented) A pharmaceutical composition comprising a disorazole compound of the general formula I as claimed in Claim 1:



Formula I

in which independently of one another

R1 is:

(i) hydrogen,

(ii) OR4,

(iii) part of a double bond to C5',

R2, and R4 are:

(i) hydrogen,

(ii) unsubstituted or substituted (C_1-C_6)-alkyl,

(iii) (C_1-C_4)-alkyl substituted by one or more fluorine atoms, preferably a trifluoromethyl group,

(iv) unsubstituted or substituted (C_1-C_4)-alkyl-(C_6-C_{14})-aryl, unsubstituted or substituted (C_1-C_4)-alkyl-heteroaryl,

(v) (C_1-C_4)-alkoxycarbonyl, (C_1-C_4)-alkylaminocarbonyl (C_1-C_4)-alkylaminothiocarbonyl, (C_1-C_6)-alkyl-carbonyl or (C_1-C_6)-alkoxycarbonyl-(C_1-C_6)-alkyl,

it being possible for the substitution of the alkyl radical by F, Cl, Br, I, CN, NH_2, NH-(C_1-C_{20})-alkyl, NH-(C_3-C_{12})-cycloalkyl, OH, O-(C_1-C_{20})-alkyl to take place singly or, on identical or different atoms, multiply by identical or different substituents, and it being possible for the substitution of an aryl radical by F, Cl, Br, I, CN, NH_2, NH-(C_1-C_{20})-alkyl, OH, O-(C_1-C_{20})-alkyl and/or (C_3-C_8)-heterocyclyl having 1 to 5 heteroatoms, preferably nitrogen, oxygen, sulfur to take place singly or, on identical or different atoms, multiply by identical or different substituents,

R3 is:

(i) unsubstituted or substituted (C_1-C_6)-alkyl,

(ii) (C_1-C_4)-alkyl substituted by one or more fluorine atoms, preferably a trifluoromethyl group,

(iii) unsubstituted or substituted (C_1-C_4)-alkyl-(C_6-C_{14})-aryl, unsubstituted or substituted (C_1-C_4)-alkyl-heteroaryl

(iv) (C_1-C_4)-alkoxycarbonyl, (C_1-C_4)-alkylaminocarbonyl (C_1-C_4)-alkylaminothiocarbonyl, (C_1-C_6)-alkyl-carbonyl or (C_1-C_6)-alkoxycarbonyl-(C_1-C_6)-alkyl,

it being possible for the substitution of the alkyl radical by F, Cl, Br, I, CN, NH_2, NH-(C_1-C_{20})-alkyl, NH-(C_3-C_{12})-cycloalkyl, OH, O-(C_1-C_{20})-alkyl to take place singly or, on identical or different atoms, multiply by identical or different substituents, and it being possible for the substitution of an aryl radical by F, Cl, Br, I, CN, NH_2, NH-(C_1-C_{20})-alkyl, OH, O-(C_1-C_{20})-alkyl and/or (C_3-C_8)-heterocyclyl having 1 to 5 heteroatoms, preferably nitrogen, oxygen, sulfur to take

place singly or, on identical or different atoms, multiply by identical or different substituents,

and

X, Y are: in each case individually independently of one another or together oxygen, sulfur, two vicinal hydroxyl groups, two vicinal methoxy groups, part of a double bond,

its tautomers, E/Z isomers, stereoisomers, including the diastereomers and enantiomers, and the physiologically tolerable salts thereof,

and a pharmaceutically acceptable carrier, diluent or excipient.

4. (Cancelled)

5. (Cancelled)

6. (Cancelled)

7. (Cancelled)

8. (Cancelled)

9. (Cancelled)

10. (Cancelled).

11. (Cancelled).

12. (Cancelled).

13. (Cancelled).

14. (Previously Presented) The pharmaceutical composition of claim 3, which is in the form of a solution, suspension, emulsion, foam, ointment, paste, patch or implant.

15. (Cancelled)

16. (Cancelled)

17. (Cancelled)

18. (Cancelled)